Adjunctive triamcinolone acetonide for Ahmed glaucoma valve implantation: a randomized clinical trial
| Autor: | Shahin Yazdani, Azadeh Doozandeh, Mehdi Yaseri, Vahid Ownagh, Mohammad Pakravan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Intraocular pressure Triamcinolone acetonide Visual acuity genetic structures medicine.medical_treatment Visual Acuity Glaucoma Glaucoma valve Triamcinolone Acetonide law.invention Prosthesis Implantation 03 medical and health sciences Tonometry Ocular Young Adult 0302 clinical medicine Postoperative Complications Randomized controlled trial Refractory law Ophthalmology medicine Glaucoma surgery Humans Postoperative Period Glaucoma Drainage Implants Intraocular Pressure Aged business.industry General Medicine Middle Aged medicine.disease eye diseases 030104 developmental biology 030221 ophthalmology & optometry Linear Models Female sense organs medicine.symptom business medicine.drug Follow-Up Studies |
| Zdroj: | European journal of ophthalmology. 27(4) |
| ISSN: | 1724-6016 |
| Popis: | PurposeTo evaluate the effect of intraoperative sub-Tenon injection of triamcinolone acetonide (TA) as an adjunct to Ahmed glaucoma valve (AGV) implantation.MethodsIn this triple-blind randomized clinical trial, 104 eyes with refractory glaucoma were randomly assigned to conventional AGV (non-TA group) or AGV with adjunctive triamcinolone (TA group). In the TA group, 10 mg TA was injected in the sub-Tenon space around the AGV plate intraoperatively. Patients were followed for 1 year. The main outcome measure was intraocular pressure (IOP). Other outcome measures included best-corrected visual acuity (BCVA), occurrence of hypertensive phase (HP), peak IOP, number of antiglaucoma medications, and complications.ResultsA total of 90 patients were included in the final analysis. Mean IOP was lower in the TA group at most follow-up visits; however, the difference was statistically significant only at the first month (p = 0.004). Linear mixed model showed that mean IOP was 1.5 mm Hg lower in the TA group throughout the study period (p = 0.006). Peak postoperative IOP was significantly lower in the TA group (19.3 ± 4.8 mm Hg versus 29 ± 9.2 mm Hg, p = 0.032). Rates of success (defined as 6 < IOP 2 lines was more common in the non-TA group (p = 0.032).ConclusionsAdjunctive intraoperative TA injection during AGV implantation can blunt peak IOP levels and reduce mean IOP up to 1 year. Visual outcomes also seem to be superior to standard surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|